Ocuphire Pharma begins patient enrolment for Nyxol phase 3 trial
Ocuphire Pharma said that it has enrolled the first subjects in the MIRA-3 phase 3 clinical trial of Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis. According to the US-based clinical-stage ophthalmic biopharma company, with half a dozen sites are enrolling patients within days of activation and 10 more sites likely to begin screening […]